Personalis’ CEO, John West, first became involved in DNA sequencing and DNA sequence interpretation in 1982. In the 1980’s, he led the development of an automated DNA sequencing system based on pattern recognition from autoradiographs, and licensed software from the lab of Roger Staden at MRC Cambridge, UK for sequence assembly and analysis. In the 1990’s Mr. West was General Manager and subsequently President of Princeton Instruments, a company focused on low light scientific imaging. This technology was used in a number of fluorescent automated DNA sequencing developments. In 2001 Mr. West joined then market leader Applied Biosystems as Vice President of Genetic Analysis. He was subsequently promoted to VP, DNA Platforms. While at Applied Biosystems Mr. West’s group introduced the model 3730xl Genetic Analyzer. This product became the mainstay of almost every major genome center in the world.
In 2004, Mr. West moved to be CEO of Solexa Ltd, a venture capital backed UK company focused primarily on single-molecule DNA sequencing. Mr. West realized that the company’s recent acquisition of DNA cluster technology could be transformative. In 2005 he led Solexa’s reverse merger into US-based and Nasdaq-listed Lynx Therapeutics, and led two PIPE financings totaling almost $100M. The company introduced its first system in mid-2006. Mr. West negotiated the January 2007 acquisition of Solexa by Illumina, Inc for approximately $600M, and stayed as VP of the DNA sequencing business there into 2008. During this time, Illumina became the world leader in next generation DNA sequencing.
From 2009 through mid-2011 Mr. West served as CEO of ViaCyte, Inc, a company leveraging stem cell technology to develop a diabetes cell therapy.
In late 2009 Mr. West’s family became the first healthy family of four to be sequenced. Their experience working with the Stanford team on genome interpretation led to the foundation of Personalis.
Mr. West received a BS and MS engineering degrees from MIT, and earned an MBA from the University of Pennsylvania’s Wharton School of Business.
What is John Stephen West's net worth?
The estimated net worth of John Stephen West is at least $1.33 million as of May 16th, 2022. Mr. West owns 382,444 shares of Personalis stock worth more than $1,327,081 as of November 22nd. This net worth estimate does not reflect any other investments that Mr. West may own. Learn More about John Stephen West's net worth.
How do I contact John Stephen West?
Has John Stephen West been buying or selling shares of Personalis?
John Stephen West has not been actively trading shares of Personalis over the course of the past ninety days. Most recently, John Stephen West sold 2,408 shares of the business's stock in a transaction on Monday, May 16th. The shares were sold at an average price of $4.86, for a transaction totalling $11,702.88. Following the completion of the sale, the chief executive officer now directly owns 382,444 shares of the company's stock, valued at $1,858,677.84. Learn More on John Stephen West's trading history.
Who are Personalis' active insiders?
Are insiders buying or selling shares of Personalis?
In the last year, insiders at the sold shares 14 times. They sold a total of 27,887 shares worth more than $51,052.75. The most recent insider tranaction occured on November, 18th when CFO Aaron Tachibana sold 1,307 shares worth more than $4,953.53. Insiders at Personalis own 4.1% of the company.
Learn More about insider trades at Personalis. Information on this page was last updated on 11/18/2024.
